These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22277284)

  • 21. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states.
    Lipman SA; Brouwer WBF; Attema AE
    Eur J Health Econ; 2019 Apr; 20(3):419-426. PubMed ID: 30229374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health outcomes in economic evaluation: the QALY and utilities.
    Whitehead SJ; Ali S
    Br Med Bull; 2010; 96():5-21. PubMed ID: 21037243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence.
    Bleichrodt H; Johannesson M
    Med Decis Making; 1997; 17(1):21-32. PubMed ID: 8994148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of subjective life expectancy on health state valuations using a 10 year TTO.
    van Nooten FE; Koolman X; Brouwer WB
    Health Econ; 2009 May; 18(5):549-58. PubMed ID: 18702082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states.
    Brown MM; Brown GC; Sharma S; Busbee B
    Ophthalmology; 2003 Jun; 110(6):1076-81. PubMed ID: 12799229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    J Health Econ; 2012 Jan; 31(1):158-68. PubMed ID: 22018622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A semi-separable utility function for health profiles.
    Guerrero AM; Herrero C
    J Health Econ; 2005 Jan; 24(1):33-54. PubMed ID: 15617787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
    Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
    Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a better QALY model.
    Abellán-Perpiñán JM; Pinto-Prades JL; Méndez-Martínez I; Badía-Llach X
    Health Econ; 2006 Jul; 15(7):665-76. PubMed ID: 16518836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A theoretical framework for TTO valuations of health.
    Buckingham K; Devlin N
    Health Econ; 2006 Oct; 15(10):1149-54. PubMed ID: 16786547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing treatment outcomes using utility assessment for health-related quality of life.
    Kattan MW
    Oncology (Williston Park); 2003 Dec; 17(12):1687-93; discussion 1693-4, 1697, 1701. PubMed ID: 14723008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Setting Dead at Zero: Applying Scale Properties to the QALY Model.
    Roudijk B; Donders ART; Stalmeier PFM
    Med Decis Making; 2018 Aug; 38(6):627-634. PubMed ID: 29629848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health utility and economic analysis: theoretical and practical issues.
    Payakachat N; Murawski MM; Summers KH
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):289-92. PubMed ID: 19670986
    [No Abstract]   [Full Text] [Related]  

  • 36. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of early noninvasive ventilation for ALS patients.
    Gruis KL; Chernew ME; Brown DL
    BMC Health Serv Res; 2005 Aug; 5():58. PubMed ID: 16131401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health related utility measurement: an introduction.
    Bakker C; van der Linden S
    J Rheumatol; 1995 Jun; 22(6):1197-9. PubMed ID: 7674256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.